norfloxacin has been researched along with Infections, Proteus in 7 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "28 patients with urinary tract infections (UTI) were treated with norfloxacin 2 X 400 mg daily for 9 days." | 7.67 | [Norfloxacin in the treatment of urinary tract infections]. ( Joost, J, 1986) |
| "28 patients with urinary tract infections (UTI) were treated with norfloxacin 2 X 400 mg daily for 9 days." | 3.67 | [Norfloxacin in the treatment of urinary tract infections]. ( Joost, J, 1986) |
| "Feline otitis externa is a dermatological disorder with a multifactorial complex etiology." | 1.62 | Otodectic and bacterial etiology of feline otitis externa in Tripoli, Libya. ( Altaeb, AA; Bennour, EM; Duro, EM; Ellraiss, OM; Elmishri, RA; Hiblu, MA; Karim, ES, 2021) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hiblu, MA | 1 |
| Ellraiss, OM | 1 |
| Karim, ES | 1 |
| Elmishri, RA | 1 |
| Duro, EM | 1 |
| Altaeb, AA | 1 |
| Bennour, EM | 1 |
| Wilson, C | 1 |
| Senior, BW | 1 |
| Tiwana, H | 1 |
| Caparros-Wanderley, W | 1 |
| Ebringer, A | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Dubini, F | 1 |
| Riviera, L | 1 |
| Visconti, A | 1 |
| Fernandes, PB | 1 |
| Chu, DT | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Shipkowitz, N | 1 |
| Joost, J | 1 |
| Muzzonigro, G | 1 |
| Caraceni, E | 1 |
| Baldassari, M | 1 |
| Ippoliti, L | 1 |
| Polito, M | 1 |
7 other studies available for norfloxacin and Infections, Proteus
| Article | Year |
|---|---|
Otodectic and bacterial etiology of feline otitis externa in Tripoli, Libya.
Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Female; Gentamicins; Libya; Male; Mite Infestati | 2021 |
Antibiotic sensitivity and proticine typing of Proteus mirabilis strains associated with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Arthritis | 1998 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
[Experimental cystitis in the rat and the therapeutic effect of a single dose of fosfomycin trometamol].
Topics: Animals; Cystitis; Drug Combinations; Drug Evaluation, Preclinical; Escherichia coli Infections; Fos | 1987 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
[Norfloxacin in the treatment of urinary tract infections].
Topics: Adolescent; Adult; Aged; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norfloxacin | 1986 |
Norfloxacin treatment in urinary tract infections by urease-producing bacteria accompanying renal calculi. Our experience.
Topics: Adult; Female; Humans; Kidney Calculi; Male; Middle Aged; Norfloxacin; Proteus; Proteus Infections; | 1985 |